Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on August 26, 2021. The filing addresses Item 5.02 regarding the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments and equity awards.
Material Changes
Effective July 1, 2021, the Board of Directors approved increases to the annual base salaries of four executive officers to align with median market levels. Additionally, the target annual performance bonus for the CEO was increased, and Restricted Stock Units (RSUs) were awarded to all four executives.
- CEO (Ankit Mahadevia, M.D.): Base salary increased from $565,000 to $620,000. Target bonus increased from 50% to 60% of base salary. Awarded 78,219 RSUs.
- CFO (Satyavrat Shukla): Base salary increased from $425,000 to $460,000. Target bonus remained at 40% of base salary. Awarded 24,067 RSUs.
- COO (Cristina Larkin): Base salary increased from $430,000 to $495,000. Target bonus remained at 40% of base salary. Awarded 24,067 RSUs.
- CMO (David Melnick, M.D.): Base salary increased from $430,000 to $480,000. Target bonus remained at 40% of base salary. Awarded 24,067 RSUs.
2021 bonus payments will be pro-rated based on the new salary and target bonus structures. The RSUs vest in four equal annual installments contingent on continued service.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The compensation changes were driven by market data indicating that prior cash compensation levels were below the median.
Investor Verification Checklist
- Verify the pro-rated calculation for 2021 performance bonuses based on the July 1, 2021 effective date.
- Review the vesting schedule and forfeiture conditions in the Restricted Stock Unit Agreement (Exhibit 10.1).
- Confirm the total number of shares authorized under the 2017 Stock Incentive Plan to assess the impact of these new awards.
- Monitor future filings for the actual achievement of corporate and individual performance goals required for bonus payouts.